Opinion

Do Dendreon’s troubles with over-optimistic sales forecasts put a cap on the promise of personalized medicine?

Industry and FDA can—and must—do more to protect global pharmaceutical supply chains

Belief that today’s commercial model is “broken” elicits a wide range of responses from industry

A supply chain perspective on marketing operations can reduce cost and complexity while improving results

Redesigning supply chains could change the shape of bio/pharma

Specialty pharmacies are competing to position themselves as the best partners for manufacturers dealing with high-touch, high-risk products

Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market

GSK invests in online resources to address ‘the whole patient’

International efforts to standardize guidelines for observational research could move the entire field forward

Just as the pharma industry is feeling price and margin pressure, so are wholesalers in today’s healthcare marketplace

Both promise and peril exist for drugmakers in working with diagnostic tests to commercialize new medications or refine the applicability of existing ones

Not all managed care plans have the same influence on overall prescribing behavior, and not all geographies operate the same way

More personal control over healthcare and the desire for more access to information drive consumer attitudes

Court rulings begin to swing toward categorizing pharma reps as hourly workers

The biopharma company’s annual report provides clarity to a confusing marketplace

Following are excerpts from the keynote presentation of Steven C. Anderson, president and CEO of the National Assn. of Chain Drug Stores, at its annual meeting, Palm Beach, FL, Apr. 25.

CMS will be changing reimbursement practices regardless of how healthcare reform plays out

Industry anticipates meaningful guidance from FDA on use of social media